Protalix BioTherapeutics Past Earnings Performance
Past criteria checks 0/6
Protalix BioTherapeutics has been growing earnings at an average annual rate of 25.2%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been declining at an average rate of 0.6% per year.
Key information
25.2%
Earnings growth rate
50.6%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | -0.6% |
| Return on equity | -51.4% |
| Net Margin | -38.6% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Protalix BioTherapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 38 | -15 | 14 | 13 |
| 31 Mar 24 | 60 | 7 | 15 | 14 |
| 31 Dec 23 | 65 | 8 | 15 | 17 |
| 30 Sep 23 | 64 | 11 | 14 | 20 |
| 30 Jun 23 | 67 | 9 | 13 | 23 |
| 31 Mar 23 | 41 | -16 | 12 | 26 |
| 31 Dec 22 | 48 | -15 | 12 | 29 |
| 30 Sep 22 | 48 | -18 | 12 | 31 |
| 30 Jun 22 | 45 | -18 | 12 | 31 |
| 31 Mar 22 | 43 | -24 | 13 | 31 |
| 31 Dec 21 | 38 | -28 | 13 | 30 |
| 30 Sep 21 | 49 | -21 | 12 | 33 |
| 30 Jun 21 | 48 | -21 | 12 | 33 |
| 31 Mar 21 | 53 | -14 | 11 | 35 |
| 31 Dec 20 | 63 | -7 | 11 | 38 |
| 30 Sep 20 | 61 | -7 | 11 | 37 |
| 30 Jun 20 | 65 | -6 | 11 | 39 |
| 31 Mar 20 | 66 | -9 | 11 | 43 |
| 31 Dec 19 | 55 | -18 | 10 | 45 |
| 30 Sep 19 | 47 | -24 | 9 | 45 |
| 30 Jun 19 | 45 | -26 | 11 | 45 |
| 31 Mar 19 | 38 | -26 | 11 | 39 |
| 31 Dec 18 | 34 | -26 | 11 | 33 |
| 30 Sep 18 | 28 | -34 | 13 | 32 |
| 30 Jun 18 | 23 | -40 | 12 | 28 |
| 31 Mar 18 | 25 | -32 | 12 | 30 |
| 31 Dec 17 | 21 | -83 | 12 | 29 |
| 30 Sep 17 | 19 | -73 | 12 | 25 |
| 30 Jun 17 | 16 | -69 | 12 | 23 |
| 31 Mar 17 | 11 | -80 | 11 | 22 |
| 31 Dec 16 | 9 | -29 | 10 | 24 |
| 30 Sep 16 | 7 | -35 | 9 | 24 |
| 30 Jun 16 | 4 | -34 | 9 | 23 |
| 31 Mar 16 | 3 | -29 | 8 | 20 |
| 31 Dec 15 | 4 | -27 | 8 | 19 |
| 30 Sep 15 | -6 | -31 | 9 | 18 |
| 30 Jun 15 | -4 | -33 | 9 | 20 |
| 31 Mar 15 | -2 | -32 | 8 | 20 |
| 31 Dec 14 | 4 | -33 | 10 | 21 |
| 30 Sep 14 | 15 | -32 | 10 | 25 |
| 30 Jun 14 | 15 | -30 | 9 | 24 |
| 31 Mar 14 | 15 | -31 | 10 | 26 |
Quality Earnings: PBDA is currently unprofitable.
Growing Profit Margin: PBDA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PBDA is unprofitable, but has reduced losses over the past 5 years at a rate of 25.2% per year.
Accelerating Growth: Unable to compare PBDA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PBDA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-20.8%).
Return on Equity
High ROE: PBDA has a negative Return on Equity (-51.41%), as it is currently unprofitable.